Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant.

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Frans M. Verduyn Lunel,

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

How to Treat MDS without Stem Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Access to Hematopoietic Cell Transplantation in the United States

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells.

BK Virus Infection Is Associated with Hematuria and Renal Impairment in Recipients of Allogeneic Hematopoetic Stem Cell Transplants Peter H. O'Donnell,

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease Paul J. Martin, Barry.

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal.

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

B Cells and Transplantation: An Educational Resource

On Modeling Human Leukocyte Antigen–Identical Sibling Match Probability for Allogeneic Hematopoietic Cell Transplantation: Estimating the Need for an.

Biology of Blood and Marrow Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia Jingmei.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902.

Lung Function, Pulmonary Complications, and Mortality after Allogeneic Blood and Marrow Transplantation in Children Zühre Kaya, Daniel J. Weiner, Deniz.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Steven M. Trifilio, Judy Pi, Jayesh Mehta

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

The Effect of Unrelated Donor Marrow Transplantation on Health-Related Quality of Life: A Report of the Unrelated Donor Marrow Transplantation Trial (T-Cell.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Validation of the Hematopoietic Cell Transplantation–Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation Muthu Veeraputhiran,

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched.

Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and.

Blood and Marrow Transplant Handbook

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization Elie Richa, Mona.

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic.

Presentation transcript:

Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients Lori S. Muffly, Melissa Boulukos, Kate Swanson, Masha Kocherginsky, Paula del Cerro, Linda Schroeder, Lisa Pape, Martine Extermann, Koen Van Besien, Andrew S. Artz Biology of Blood and Marrow Transplantation Volume 19, Issue 3, Pages 429-434 (March 2013) DOI: 10.1016/j.bbmt.2012.11.006 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Diagram of study accrual. Biology of Blood and Marrow Transplantation 2013 19, 429-434DOI: (10.1016/j.bbmt.2012.11.006) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Adjusted mean SF-36 PCS (A) and SF-36 MCS (B) scores for allogeneic HCT recipients compared with population age group norms. ∗Allogeneic HCT recipients aged ≥50 years. Biology of Blood and Marrow Transplantation 2013 19, 429-434DOI: (10.1016/j.bbmt.2012.11.006) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 CGA impairments by performance status. Biology of Blood and Marrow Transplantation 2013 19, 429-434DOI: (10.1016/j.bbmt.2012.11.006) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions